Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 06 Oct 2025, 22:35 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The video provides a fundamental analysis of Pfizer (PFE). The analysis emphasizes the impact of policy changes in the pharmaceutical sector and the ongoing uncertainty due to changing tariff policies under the current administration. It highlights the gap between the calculated intrinsic value per share of Pfizer at $75.25, with the market price at $27.37. The analyst explicitly reiterates a 'buy' rating for Pfizer, appealing to long-term investors based on the expectation that the company will outlast current policy implementations. The analysis is based around the difference of the current market price and the calculated value of the company taking into account market volatility due to constant policy and tariff changes, and estimates a buy for Pfizer at 75.25
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.